BrightPath Biotherapeutics

BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.

Ito Kyogo

Founder

1 past transactions

Advanced Immunotherapy

Acquisition in 2016
Advanced Immunotherapy is developing cancer immunotherapy using T-iPS cells.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.